These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36244527)

  • 1. Gabapentin increases the abuse liability of alcohol alone and in combination with oxycodone in participants with co-occurring opioid and alcohol use disorder.
    Castillo F; Jones JD; Luba RR; Mogali S; Foltin RW; Evans SM; Comer SD
    Pharmacol Biochem Behav; 2022 Nov; 221():173482. PubMed ID: 36244527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone.
    Tompkins DA; Lanier RK; Harrison JA; Strain EC; Bigelow GE
    Psychopharmacology (Berl); 2010 Jul; 210(4):471-80. PubMed ID: 20386884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subjective, psychomotor, and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteers.
    Zacny JP; Paice JA; Coalson DW
    Pharmacol Biochem Behav; 2012 Jan; 100(3):560-5. PubMed ID: 22085697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minocycline attenuates oxycodone-induced positive subjective responses in non-dependent, recreational opioid users.
    Mogali S; Askalsky P; Madera G; Jones JD; Comer SD
    Pharmacol Biochem Behav; 2021 Oct; 209():173241. PubMed ID: 34298029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subjective, psychomotor, and physiological effects of oxycodone alone and in combination with ethanol in healthy volunteers.
    Zacny JP; Gutierrez S
    Psychopharmacology (Berl); 2011 Dec; 218(3):471-81. PubMed ID: 21603891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users.
    Harris SC; Perrino PJ; Smith I; Shram MJ; Colucci SV; Bartlett C; Sellers EM
    J Clin Pharmacol; 2014 Apr; 54(4):468-77. PubMed ID: 24243216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Ibudilast on the Subjective, Reinforcing, and Analgesic Effects of Oxycodone in Recently Detoxified Adults with Opioid Dependence.
    Metz VE; Jones JD; Manubay J; Sullivan MA; Mogali S; Segoshi A; Madera G; Johnson KW; Comer SD
    Neuropsychopharmacology; 2017 Aug; 42(9):1825-1832. PubMed ID: 28393896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of tradipitant, a selective NK1 antagonist, on response to oxycodone in humans.
    Coe MA; Lofwall MR; Vessels V; Nuzzo PA; Walsh SL
    Psychopharmacology (Berl); 2021 Jul; 238(7):1857-1866. PubMed ID: 33988725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abuse potential of intravenous oxycodone/naloxone solution in nondependent recreational drug users.
    Colucci SV; Perrino PJ; Shram M; Bartlett C; Wang Y; Harris SC
    Clin Drug Investig; 2014 Jun; 34(6):421-9. PubMed ID: 24756361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies.
    Stoops WW; Hatton KW; Lofwall MR; Nuzzo PA; Walsh SL
    Psychopharmacology (Berl); 2010 Oct; 212(2):193-203. PubMed ID: 20665209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human Abuse Potential of Oral NKTR-181 in Recreational Opioid Users: A Randomized, Double-Blind, Crossover Study.
    Ge X; Henningfield JE; Siddhanti S; Jobes J; Lu L; Xie S; Ziola M; Kelsh D; Vince B; Di Fonzo CJ; Tagliaferri M; Zalevsky J; Doberstein SK; Hoch U; Eldon MA
    Pain Med; 2020 Feb; 21(2):e114-e126. PubMed ID: 31553457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute Experimental Pain Responses in Methadone- and Buprenorphine/Naloxone-Maintained Patients Administered Additional Opioid or Gabapentin: A Double-Blind Crossover Pilot Study.
    Murnion BP; Rivas C; Demirkol A; Hayes V; Lintzeris N; Nielsen S
    Pain Med; 2020 Jun; 21(6):1188-1198. PubMed ID: 31504868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal abuse potential of an abuse-deterrent oxycodone formulation compared to oxycodone immediate release and placebo in nondependent, recreational opioid users.
    Setnik B; Schoedel K; Bartlett C; Dick C; Hakim N; Geoffroy P
    J Opioid Manag; 2017; 13(6):449-464. PubMed ID: 29308591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Within-subject comparison of the psychopharmacological profiles of oral hydrocodone and oxycodone combination products in non-drug-abusing volunteers.
    Zacny JP; Gutierrez S
    Drug Alcohol Depend; 2009 Apr; 101(1-2):107-14. PubMed ID: 19118954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the NK1 antagonist, aprepitant, on response to oral and intranasal oxycodone in prescription opioid abusers.
    Walsh SL; Heilig M; Nuzzo PA; Henderson P; Lofwall MR
    Addict Biol; 2013 Mar; 18(2):332-43. PubMed ID: 22260216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute administration of oxycodone, alcohol, and their combination on simulated driving-preliminary outcomes in healthy adults.
    Babalonis S; Coe MA; Nuzzo PA; Lofwall MR; Ali N; Sloan PA; Fanucchi LC; Walsh SL
    Psychopharmacology (Berl); 2021 Feb; 238(2):539-549. PubMed ID: 33169203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opioid abusers' ability to differentiate an opioid from placebo in laboratory challenge testing.
    Antoine DG; Strain EC; Tompkins DA; Bigelow GE
    Drug Alcohol Depend; 2013 Sep; 132(1-2):369-72. PubMed ID: 23369645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human Abuse Potential of the New Opioid Analgesic Molecule NKTR-181 Compared with Oxycodone.
    Webster L; Henningfield J; Buchhalter AR; Siddhanti S; Lu L; Odinecs A; Di Fonzo CJ; Eldon MA
    Pain Med; 2018 Feb; 19(2):307-318. PubMed ID: 28340145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Within-subject comparison of the psychopharmacological profiles of oral oxycodone and oral morphine in non-drug-abusing volunteers.
    Zacny JP; Lichtor SA
    Psychopharmacology (Berl); 2008 Jan; 196(1):105-16. PubMed ID: 17899018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gabapentin enacarbil and morphine administered in combination versus alone: a double-blind, randomized, pharmacokinetic, and tolerability comparison.
    Chen C; Upward J; Arumugham T; Stier B; Davy M
    Clin Ther; 2015 Feb; 37(2):349-57. PubMed ID: 25467190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.